125 related articles for article (PubMed ID: 21074309)
1. Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors.
Zhang Z; Liao H; Chen X; Zheng Y; Liu Y; Tao X; Gu C; Dong L; Duan T; Yang Y; Liu X; Yu Y; Feng Y
Eur J Obstet Gynecol Reprod Biol; 2011 Mar; 155(1):69-74. PubMed ID: 21074309
[TBL] [Abstract][Full Text] [Related]
2. The combined effect of survivin-targeted shRNA and emodin on the proliferation and invasion of ovarian cancer cells.
Xue H; Chen Y; Cai X; Zhao L; He A; Guo K; Zheng X
Anticancer Drugs; 2013 Oct; 24(9):937-44. PubMed ID: 23921083
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.
Runnebaum IB; Brüning A
Clin Cancer Res; 2005 Sep; 11(17):6325-32. PubMed ID: 16144937
[TBL] [Abstract][Full Text] [Related]
4. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides.
Ma X; Wang S; Zhou J; Xing H; Xu G; Wang B; Chen G; Lu YP; Ma D
Oncol Rep; 2005 Jul; 14(1):275-9. PubMed ID: 15944801
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
7. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
[TBL] [Abstract][Full Text] [Related]
8. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.
Warrenfeltz SW; Lott SA; Palmer TM; Gray JC; Puett D
Mol Cancer Res; 2008 Nov; 6(11):1775-85. PubMed ID: 19010824
[TBL] [Abstract][Full Text] [Related]
9. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
Chen L; Liang L; Yan X; Liu N; Gong L; Pan S; Lin F; Zhang Q; Zhao H; Zheng F
Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells.
Song YC; Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():26-34. PubMed ID: 17404014
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells.
Jiang L; Luo RY; Yang J; Cheng YX
Mol Med Rep; 2013 Feb; 7(2):425-30. PubMed ID: 23229441
[TBL] [Abstract][Full Text] [Related]
12. FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5.
Huang Y; Jin H; Liu Y; Zhou J; Ding J; Cheng KW; Yu Y; Feng Y
Endocr Relat Cancer; 2011 Feb; 18(1):13-26. PubMed ID: 20943720
[TBL] [Abstract][Full Text] [Related]
13. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
14. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.
Furui T; LaPushin R; Mao M; Khan H; Watt SR; Watt MA; Lu Y; Fang X; Tsutsui S; Siddik ZH; Bast RC; Mills GB
Clin Cancer Res; 1999 Dec; 5(12):4308-18. PubMed ID: 10632375
[TBL] [Abstract][Full Text] [Related]
16. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
17. [Proteasome inhibitors sensitize ovarian cancer cells to cisplatin].
Li Y; Weng DH; Kong FF; Fan LS; Hu Y; Song XH; Xing H; Wang W; Ma D; Wang SX
Zhonghua Fu Chan Ke Za Zhi; 2010 Jun; 45(6):445-8. PubMed ID: 21029596
[TBL] [Abstract][Full Text] [Related]
18. Luteinizing hormone inhibits Fas-induced apoptosis in ovarian surface epithelial cell lines.
Slot KA; de Boer-Brouwer M; Houweling M; Vaandrager AB; Dorrington JH; Teerds KJ
J Endocrinol; 2006 Feb; 188(2):227-39. PubMed ID: 16461549
[TBL] [Abstract][Full Text] [Related]
19. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.
Yu W; Shun MC; Anderson K; Chen H; Sanders BG; Kline K
Apoptosis; 2006 Oct; 11(10):1813-23. PubMed ID: 16850165
[TBL] [Abstract][Full Text] [Related]
20. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy.
Zhang HY; Zhang PN; Sun H
Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):81-6. PubMed ID: 19540648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
